Abeona Therapeutics (ABEO) Stock Forecast, Price Target & Predictions
ABEO Stock Forecast
Abeona Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 7.53% upside from ABEO’s last price of $5.58) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ABEO Price Target
The average price target for Abeona Therapeutics (ABEO) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 7.53% upside from ABEO's last price of $5.58.
ABEO Analyst Ratings
According to 3 Wall Street analysts, Abeona Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ABEO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Abeona Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | - | Leerink Partners | $6.00 | $4.15 | 44.58% | 7.53% |
The latest Abeona Therapeutics stock forecast, released on Nov 14, 2022 by Leerink Partners company, set a price target of $6.00, which represents a 44.58% increase from the stock price at the time of the forecast ($4.15), and a 7.53% increase from ABEO last price ($5.58).
Abeona Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.58 | $5.58 | $5.58 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Abeona Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Abeona Therapeutics's last price of $5.58. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 03, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 16, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Nov 14, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Abeona Therapeutics's last stock rating was published by H.C. Wainwright on Jul 03, 2024. The company Initialise its ABEO rating from "null" to "Buy".
Abeona Therapeutics Financial Forecast
Abeona Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | Sep 15 | Jun 15 | Mar 12 | Mar 11 | Sep 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $68.00K | $346.00K | $3.00M | $7.00M | - | - | - | $1.71M | $819.00K | $2.60M | $219.00K | $217.00K | $186.00K | $184.00K | $214.00K | $235.00K | $285.00K | $282.00K | $1.85M | $150.00K | $127.00K |
| Avg Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.67K | - | $1.00M | $253.73K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $1.92M | $212.80K | $559.44K | $304.62K | $157.14K | $219.23K | $427.50K | $168.00K | $183.53K | $192.38K | $232.65K | $2.58M | $160.71K | $79.44K |
| High Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.67K | - | $1.00M | $304.48K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $2.31M | $255.36K | $671.33K | $365.54K | $188.57K | $263.07K | $513.00K | $201.60K | $220.23K | $230.85K | $279.18K | $3.09M | $192.86K | $95.33K |
| Low Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.67K | - | $1.00M | $202.99K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $1.54M | $170.24K | $447.55K | $243.69K | $125.71K | $175.38K | $342.00K | $134.40K | $146.82K | $153.90K | $186.12K | $2.06M | $128.57K | $63.55K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 3 | 17 | 11 | 8 | 12 | 7 | 7 | 17 | 8 | 18 | 10 | 11 | 20 | 11 | 7 | 19 | 9 | 10 | 14 | 10 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.07% | 1.36% | 0.56% | 5.00% | - | - | - | 0.89% | 3.85% | 4.64% | 0.72% | 1.38% | 0.85% | 0.43% | 1.27% | 1.28% | 1.48% | 1.21% | 0.72% | 0.93% | 1.60% |
Abeona Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is -, with a low forecast of -, and a high forecast of -. ABEO's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $68.00K (Dec 22).
Abeona Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | Sep 15 | Jun 15 | Mar 12 | Mar 11 | Sep 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 3 | 17 | 11 | 8 | 12 | 7 | 7 | 17 | 8 | 18 | 10 | 11 | 20 | 11 | 7 | 19 | 9 | 10 | 14 | 10 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-12.49M | $-10.37M | $-13.31M | $-13.34M | $-4.81M | $-15.34M | $-21.87M | $-16.90M | $-15.91M | $-11.41M | $-8.29M | $-5.20M | $-8.07M | $-5.00M | $-2.40M | $-6.52M | $-5.37M | $-5.92M | $-3.98M | $-4.67M | $-1.67M | $-12.51M |
| Avg Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-100.00K | - | $-600.00K | $-9.52M | $-3.22M | $-840.00K | $-18.48M | $-13.12M | $-13.20M | $-11.02M | $-7.80M | $-8.72M | $-6.65M | $-4.84M | $-5.66M | $-3.41M | $-4.89M | $-3.72M | $-3.07M | $-3.13M | $-11.41M | $-1.78M | $-5.00M |
| High Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-100.00K | - | $-600.00K | $-7.62M | $-3.22M | $-840.00K | $-14.78M | $-10.50M | $-10.56M | $-8.81M | $-6.24M | $-6.98M | $-5.32M | $-3.87M | $-4.53M | $-2.73M | $-3.91M | $-2.97M | $-2.46M | $-2.51M | $-9.12M | $-1.43M | $-4.00M |
| Low Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-100.00K | - | $-600.00K | $-11.43M | $-3.22M | $-840.00K | $-22.17M | $-15.74M | $-15.84M | $-13.22M | $-9.37M | $-10.47M | $-7.98M | $-5.81M | $-6.79M | $-4.09M | $-5.87M | $-4.46M | $-3.68M | $-3.76M | $-13.69M | $-2.14M | $-6.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | 17.29% | 1.40% | 4.14% | 5.72% | 0.83% | 1.67% | 1.28% | 1.44% | 1.46% | 0.95% | 0.78% | 1.67% | 0.88% | 0.70% | 1.33% | 1.44% | 1.93% | 1.27% | 0.41% | 0.94% | 2.50% |
undefined analysts predict ABEO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Abeona Therapeutics's previous annual EBITDA (undefined) of $NaN.
Abeona Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | Sep 15 | Jun 15 | Mar 12 | Mar 11 | Sep 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 3 | 17 | 11 | 8 | 12 | 7 | 7 | 17 | 8 | 18 | 10 | 11 | 20 | 11 | 7 | 19 | 9 | 10 | 14 | 10 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-16.59M | $6.42M | $-20.99M | $-15.83M | $-7.24M | $-17.37M | $-23.92M | $-18.55M | $-16.42M | $-11.70M | $-8.46M | $-5.34M | $-8.28M | $-5.25M | $-2.62M | $-6.70M | $-5.54M | $-6.07M | $-4.11M | $-4.89M | $-1.90M | $-12.72M |
| Avg Forecast | $-7.68M | $-16.65M | $-19.98M | $-19.47M | $-19.34M | $-19.21M | $-17.52M | $-26.30M | $-12.01M | $-38.42M | $-10.16M | $-63.89M | $-91.58M | $-20.93M | $-14.35M | $-14.50M | $-11.37M | $-8.01M | $-8.91M | $-6.83M | $-4.97M | $-5.95M | $-3.73M | $-5.03M | $-3.84M | $-3.15M | $-3.24M | $-11.95M | $-2.03M | $-5.09M |
| High Forecast | $-7.68M | $-16.65M | $-19.98M | $-19.47M | $-19.34M | $-18.20M | $-17.52M | $-26.30M | $-12.01M | $-38.42M | $-8.13M | $-63.89M | $-91.58M | $-16.74M | $-11.48M | $-11.60M | $-9.09M | $-6.40M | $-7.13M | $-5.46M | $-3.97M | $-4.76M | $-2.98M | $-4.02M | $-3.07M | $-2.52M | $-2.59M | $-9.56M | $-1.62M | $-4.07M |
| Low Forecast | $-7.68M | $-16.65M | $-19.98M | $-19.47M | $-19.34M | $-20.22M | $-17.52M | $-26.30M | $-12.01M | $-38.42M | $-12.20M | $-63.89M | $-91.58M | $-25.11M | $-17.23M | $-17.40M | $-13.64M | $-9.61M | $-10.69M | $-8.19M | $-5.96M | $-7.14M | $-4.47M | $-6.03M | $-4.61M | $-3.78M | $-3.89M | $-14.34M | $-2.43M | $-6.11M |
| Surprise % | - | - | - | - | - | - | - | - | 1.38% | -0.17% | 2.07% | 0.25% | 0.08% | 0.83% | 1.67% | 1.28% | 1.44% | 1.46% | 0.95% | 0.78% | 1.67% | 0.88% | 0.70% | 1.33% | 1.44% | 1.93% | 1.27% | 0.41% | 0.94% | 2.50% |
Abeona Therapeutics's average Quarter net income forecast for Dec 23 is $-12.01M, with a range of $-12.01M to $-12.01M. ABEO's average Quarter net income forecast represents a -287.24% decrease compared to the company's last Quarter net income of $6.42M (Dec 22).
Abeona Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | Sep 15 | Jun 15 | Mar 12 | Mar 11 | Sep 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 3 | 17 | 11 | 8 | 12 | 7 | 7 | 17 | 8 | 18 | 10 | 11 | 20 | 11 | 7 | 19 | 9 | 10 | 14 | 10 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $5.11M | $5.68M | $4.22M | $7.40M | $4.43M | $4.70M | $5.61M | $5.66M | $4.97M | $4.63M | $2.88M | $2.17M | $2.64M | $3.02M | $2.39M | $3.73M | $4.37M | $4.72M | $3.67M | $979.00K | $1.03M | $1.17M |
| Avg Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $938.48K | - | $5.63M | $1.43M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $10.83M | $1.20M | $3.15M | $1.72M | $884.85K | $1.23M | $2.41M | $945.99K | $1.03M | $1.08M | $1.31M | $2.39M | $904.96K | $447.34K |
| High Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $938.48K | - | $5.63M | $1.71M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $13.00M | $1.44M | $3.78M | $2.06M | $1.06M | $1.48M | $2.89M | $1.14M | $1.24M | $1.30M | $1.57M | $2.87M | $1.09M | $536.80K |
| Low Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $938.48K | - | $5.63M | $1.14M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $8.67M | $958.60K | $2.52M | $1.37M | $707.88K | $987.56K | $1.93M | $756.79K | $826.74K | $866.59K | $1.05M | $1.91M | $723.96K | $357.87K |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 2.96% | 0.24% | 0.56% | 6.96% | 3.32% | 1.29% | 0.46% | 3.86% | 0.91% | 1.26% | 2.99% | 2.45% | 0.99% | 3.94% | 4.22% | 4.35% | 2.80% | 0.41% | 1.13% | 2.60% |
Abeona Therapeutics's average Quarter SG&A projection for Mar 24 is $938.48K, based on 4 Wall Street analysts, with a range of $938.48K to $938.48K. The forecast indicates a -81.63% fall compared to ABEO last annual SG&A of $5.11M (Dec 23).
Abeona Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | Sep 15 | Jun 15 | Mar 12 | Mar 11 | Sep 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 3 | 17 | 11 | 8 | 12 | 7 | 7 | 17 | 8 | 18 | 10 | 11 | 20 | 11 | 7 | 19 | 9 | 10 | 14 | 10 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.65 | $0.82 | $-3.62 | $-4.26 | $-1.93 | $-8.73 | $-12.22 | $-9.67 | $-8.59 | $-6.18 | $-4.50 | $-3.31 | $-5.14 | $-3.26 | $-1.97 | $-5.11 | $-4.23 | $-4.78 | $-4.00 | $-253.26 | $-123.37 | $-1.01K |
| Avg Forecast | $-0.15 | $-0.33 | $-0.39 | $-0.38 | $-0.38 | $-0.38 | $-0.34 | $-0.51 | $-0.47 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-4.50 | $-3.25 | $-5.00 | $-5.75 | $-2.25 | $-4.25 | $-6.75 | $-3.00 | $-2.25 | $-1.43 | $-1.77 | $213.75 | $-200.00 | $-55.00 |
| High Forecast | $-0.15 | $-0.33 | $-0.39 | $-0.38 | $-0.38 | $-0.36 | $-0.34 | $-0.51 | $-0.47 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-3.60 | $-2.60 | $-4.00 | $-4.60 | $-1.80 | $-3.40 | $-5.40 | $-2.40 | $-1.80 | $-1.14 | $-1.42 | $256.50 | $-160.00 | $-44.00 |
| Low Forecast | $-0.15 | $-0.33 | $-0.39 | $-0.38 | $-0.38 | $-0.39 | $-0.34 | $-0.51 | $-0.47 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-5.40 | $-3.90 | $-6.00 | $-6.90 | $-2.70 | $-5.10 | $-8.10 | $-3.60 | $-2.70 | $-1.71 | $-2.13 | $171.00 | $-240.00 | $-66.00 |
| Surprise % | - | - | - | - | - | - | - | - | 1.38% | -1.09% | 1.52% | 1.70% | 0.54% | 0.80% | 1.34% | 1.22% | 1.91% | 1.90% | 0.90% | 0.58% | 2.28% | 0.77% | 0.29% | 1.70% | 1.88% | 3.34% | 2.26% | -1.18% | 0.62% | 18.33% |
According to 3 Wall Street analysts, Abeona Therapeutics's projected average Quarter EPS for Dec 23 is $-0.47, with a low estimate of $-0.47 and a high estimate of $-0.47. This represents a -157.32% decrease compared to ABEO previous annual EPS of $0.82 (Dec 22).
Abeona Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CALA | Calithera Biosciences | $0.05 | $2.00 | 3900.00% | Hold |
| ATHA | Athira Pharma | $0.53 | $18.00 | 3296.23% | Buy |
| CKPT | Checkpoint Therapeutics | $2.30 | $20.00 | 769.57% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| IVVD | Invivyd | $1.15 | $9.50 | 726.09% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| RGNX | REGENXBIO | $12.84 | $38.00 | 195.95% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| AFMD | Affimed | $4.00 | $7.50 | 87.50% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.32 | $26.57 | 62.81% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| ABEO | Abeona Therapeutics | $5.58 | $6.00 | 7.53% | Buy |
ABEO Forecast FAQ
Is Abeona Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Abeona Therapeutics (ABEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ABEO's total ratings.
What is ABEO's price target?
Abeona Therapeutics (ABEO) average price target is $6 with a range of $6 to $6, implying a 7.53% from its last price of $5.58. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Abeona Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ABEO stock, the company can go up by 7.53% (from the last price of $5.58 to the average price target of $6), up by 7.53% based on the highest stock price target, and up by 7.53% based on the lowest stock price target.
Can Abeona Therapeutics stock reach $8?
ABEO's average twelve months analyst stock price target of $6 does not support the claim that Abeona Therapeutics can reach $8 in the near future.
What are Abeona Therapeutics's analysts' financial forecasts?
Abeona Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $466.67K (high $466.67K, low $466.67K), average EBITDA is $-280K (high $-280K, low $-280K), average net income is $-82.364M (high $-81.353M, low $-83.375M), average SG&A $2.63M (high $2.63M, low $2.63M), and average EPS is $-1.608 (high $-1.588, low $-1.628). ABEO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $12.9M (high $12.9M, low $12.9M), average EBITDA is $-7.74M (high $-7.74M, low $-7.74M), average net income is $-63.777M (high $-63.777M, low $-63.777M), average SG&A $72.64M (high $72.64M, low $72.64M), and average EPS is $-1.245 (high $-1.245, low $-1.245).
Did the ABEO's actual financial results beat the analysts' financial forecasts?
Based on Abeona Therapeutics's last annual report (Dec 2023), the company's revenue was $3.5M, beating the average analysts forecast of $0 by 0%. Apple's EBITDA was $-45.002M, beating the average prediction of $0 by 0%. The company's net income was $-54.188M, beating the average estimation of $-12.011M by 351.14%. Apple's SG&A was $17.41M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-2.53, beating the average prediction of $-0.47 by 438.30%. In terms of the last quarterly report (Dec 2022), Abeona Therapeutics's revenue was $68K, missing the average analysts' forecast of $1M by -93.20%. The company's EBITDA was $-10.372M, beating the average prediction of $-600K by 1628.67%. Abeona Therapeutics's net income was $6.42M, missing the average estimation of $-38.42M by -116.70%. The company's SG&A was $5.68M, beating the average forecast of $5.63M by 0.91%. Lastly, the company's EPS was $0.82, missing the average prediction of $-0.75 by -209.33%